| 词条 | Laniquidar |
| 释义 |
| verifiedrevid = 444169419 | IUPAC_name = methyl 11-(1- | image = Laniquidar.png | width = | image2 = | width2 = | drug_name = | tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number = 197509-46-9 | ATC_prefix = none | ATC_suffix = | ATC_supplemental = | PubChem = 6450806 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | UNII_Ref = {{fdacite|correct|FDA}} | UNII = K3FRN4DDOY | ChemSpiderID = 4953357 | chemical_formula = | C=37 | H=36 | N=4 | O=3 | molecular_weight = 584.70 g/mol | SMILES = COC(=O)C1=CN=C2N1CCC3=CC=CC=C3C2=C4CCN(CC4)CCC5=CC=C(C=C5)OCC6=NC7=CC=CC=C7C=C6 | StdInChI = 1S/C37H36N4O3/c1-43-37(42)34-24-38-36-35(32-8-4-2-6-27(32)19-23-41(34)36)29-17-21-40(22-18-29)20-16-26-10-14-31(15-11-26)44-25-30-13-12-28-7-3-5-9-33(28)39-30/h2-15,24H,16-23,25H2,1H3 | StdInChIKey = TULGGJGJQXESOO-UHFFFAOYSA-N }}Laniquidar (INN) is a P-glycoprotein inhibitor undergoing clinical studies for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).[1] References1. ^{{cite journal | last1 = Ross | first1 = DD | title = Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome | journal = Best practice & research. Clinical haematology | volume = 17 | issue = 4 | pages = 641–51 | year = 2004 | pmid = 15494300 |name-list-format=vanc | doi = 10.1016/j.beha.2004.08.014 }} {{pharma-stub}} 6 : Experimental cancer drugs|Quinolines|Phenol ethers|Piperidines|Nitrogen heterocycles|Heterocyclic compounds (3 rings) |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。